{
  "id": "605281cf94d57fd879000015",
  "type": "factoid",
  "question": "How many patients were enrolled in the FREEDOMS clinical trial?",
  "ideal_answer": "FREEDOMS study, a randomised, double-blind study included 1272 patients with relapsing-remitting MS.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22494956"
  ],
  "snippets": [
    {
      "text": "We did subgroup analyses of ARRs (primary outcome) and confirmed disability progression (a secondary outcome) over 24 months in the FREEDOMS study, a randomised, double-blind study that included 1272 patients with relapsing-remitting MS who were assigned 1:1:1 to fingolimod (0\u00b75 mg or 1\u00b725 mg) or placebo once daily for 24 months. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22494956",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "1,272"
}